GSK and Sanofi promise 200m COVID-19 vaccines to international COVAX initiative
pharmafile | October 28, 2020 | News story | Manufacturing and Production, Research and Development | COVAX, COVID-19, GSK, Sanofi
Sanofi and GSK have committed 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine to the COVAX Facility, a part of the international COVAX collaboration, to help improve access to vaccines for those that need them.
COVAX is described as the “vaccines pillar” of the Access to COVID-19 Tools (ACT) Accelerator, a global partnership with the goal of ensuring that all nations in need can access COVID-19 tests, treatments, and vaccines. As part of this new partnership, GSK and Sanofi have backed this ambition, and will be providing their vaccine to those who need it most.
“Since we started working on the development of COVID-19 vaccines, GSK has pledged to make them available to people around the world,” commented Roger Connor, President of GSK Vaccines. “We are proud to be working with Sanofi to make this adjuvanted recombinant protein-based vaccine available to the countries signed up to the COVAX Facility as soon as possible – this has the potential to be a significant contribution to the global fight against COVID-19.”
Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, also remarked: “To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control. This moment also reflects our long-term commitment to global health and ensures our COVID-19 vaccines are affordable and accessible to those most at risk, everywhere in the world.”
Spearheaded by its legal administrator Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization, COVAX is comprised of national governments, global health organisations, businesses and philanthropies around the world. Over 180 countries worldwide have signed on to help support and benefit from the COVAX Facility so far.
Sanofi and GSK are currently evaluating their COVID-19 vaccine candidate in Phase 1/2 trials, with results expected to be revealed in December this year.
Matt Fellows
Related Content
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
